Amazing stuff and complex too! This article has a total of 10 figures, each one appears to show just one aspect of the process.
"... These mutations—known as somatic hypermutations—allow B cells to produce antibodies tailor-made to recognize the foreign pathogens they just encountered, making them more efficient at defense.
This is a key part of our immune system and how it adapts to new pathogens. But how cells unleash such an extreme kind of mutation—occurring at a rate 1 million times higher than in other genetic regions—in a defined stretch of DNA has remained unclear.
Now, researchers ... have found the molecular regulators that orchestrate this delicate process. ...
Part of the challenge in studying somatic hypermutation has been the difficulty in controlling the mutation process so it could be studied experimentally. ...
Adding to the mystery is that somatic hypermutations alter a single point on a single strand of DNA. How the enzyme responsible—called activation-induced deaminase (AID)—gains access to the single-strand DNA is unclear. ..."
"... The researchers investigated three regulatory factors:
negative elongation factor (NELF), which pauses RNA polymerase II (the enzyme that copies DNA into RNA) near gene start sites;
MLLT1 and MLLT3, proteins that bind modified histones (the proteins around which DNA is wrapped); and the
integrator–protein phosphatase 2A (INT–PP2A) complex, which chemically modifies RNA polymerase II. ..."
negative elongation factor (NELF), which pauses RNA polymerase II (the enzyme that copies DNA into RNA) near gene start sites;
MLLT1 and MLLT3, proteins that bind modified histones (the proteins around which DNA is wrapped); and the
integrator–protein phosphatase 2A (INT–PP2A) complex, which chemically modifies RNA polymerase II. ..."
From the abstract:
"Somatic hypermutation (SHM) creates point mutations in the variable regions of immunoglobulin genes in activated B cells to support antibody affinity maturation. SHM is initiated by activation-induced deaminase (AID), and the single-stranded DNA substrate of this cytosine deaminase is thought to arise during RNA polymerase II (PolII) transcription, perhaps in the context of PolII stalling.
The factors and mechanisms that mediate AID chromatin recruitment and generate its putative stalled PolII substrate during SHM are unknown.
Negative elongation factor (NELF) stabilizes PolII in a paused state near the transcription start site. Release of NELF from PolII and the PolII elongation-versus-termination decision are regulated by opposing super elongation complex (SEC) kinase and integrator–protein phosphatase 2A (INT–PP2A) activities.
Here we demonstrate that NELF, the SEC components MLLT1 and MLLT3 and the INT–PP2A phosphatase module are required for SHM.
We show that NELF can associate with PolII in the AID target window in the gene body and that, in the absence of NELF, AID fails to deaminate its targets despite efficient recruitment to chromatin and transcription by PolII.
MLLT1 and MLLT3 interact with AID through their histone-binding YEATS domain and are required for AID enrichment at its target sites.
We propose a physiological function for the NELF–PolII association in gene bodies in creating the stalled PolII substrate for AID action during SHM."
Fig. 1: NELF is required for SHM.
Fig. 2: NELF is found in the AID target window with PolII.


